5/13/2021

speaker
Mel
Operator

Standing by, welcome to the Infinity Pharmaceuticals conference call to discuss the company's operations and first quarter 2021 financial results. My name is Mel, and I will be your operator for today's call. At this time, all participants are in a listen-only mode. There will be a question and answer session to follow. Please be advised that this call is being recorded at Infinity's request. Now, I would like to introduce your host for today's call, Jane Kaufman. Ma'am, please go ahead.

speaker
Jane Kaufman
Host

Thank you, Mel, and good afternoon, everyone. Welcome to today's call to discuss our recent business progress and review of our first quarter 2021 financial results. On the call with me today are Adeline Perkins, Chief Executive Officer, Larry Block, President, and Brian Schwartz, Consulting Chief Physician. We'll open the call for Q&A following our remarks. The press release issued this afternoon details our results and is available on our website at mv.com. Please note that during this call we may make forward-looking statements about our future expectations and plans, including clinical development objectives, the therapeutic potential of our product candidates, our strategic plans and strategies, and financial projections. Our actual results may differ materially from what we project today due to a number of important factors, including the considerations described in the risk factor section of our annual report on Form 10-K for 2020, and in other filings we make with the SEC. These forward-looking statements may represent our views only as of today, and we caution you that we may not update them in the future, whether as a result of new information, future events, or otherwise. Now, I'd like to turn the call over to Adeline.

speaker
Adeline Perkins
Chief Executive Officer

Thanks, Jane, and thank you to everyone for joining us today. We've reached an exciting inflection point at InfiniDate, having generated compelling data which demonstrate the broad potential of aganalysib to improve treatment regimens in multiple solid tumors. We're poised to build on this momentum with a substantial update this summer on the triple negative breast cancer data presented at the San Antonio Breast Cancer Symposium with data on at least twice as many patients, in addition to providing an update on our future plans in urothelial cancer at a planned corporate event on Tuesday, July 27th. Over the last six months, we've generated important clinical readouts from MERIA-1, MERIA-3, R2, and MERIA-275 studies across six different indications, which highlight the broad potential of aganalysib's unique macrophage-targeting immune-modulating mechanism. Our preclinical, translational, and clinical data have consistently shown that aganalysib has the potential to create a T-cell inflamed tumor microenvironment from a non-T-cell inflamed environment, sometimes simplified as turning cold tumors hot, activating an immune response, and increasing PD-L1 expression, thus priming for and increasing the effectiveness of checkpoint inhibitors regardless of baseline PD-L1 level. On today's call, our consulting chief physician, Dr. Brian Schwartz, we'll discuss next steps for our TMDC and UC programs. But before that, I'd like to briefly remind you of the data we presented over the last six months in chronological order and program guidance. First, data from MARIA-1, our Phase I 1B study in collaboration with Bristol-Myers Squibb, evaluating a GAN elicit in combination with Updivo in patients with advanced solid tumors, namely melanoma and squamous cell cancer of the head and neck, were presented at CITC in November of 2020. These data reinforce the potential of aganalysib to overcome resistance to checkpoint inhibition, including in patients who progressed on a checkpoint inhibitor as their immediate prior therapy. Second, data from the TMDC cohort of MARIO3, our phase two study in collaboration with Roche Genentech, in which we are evaluating the combination of aganalysib with ticentricinabraxane as a frontline treatment in patients with TNBC, were presented at San Antonio Breast in December of 2020. These data show a highly encouraging increase in the overall response rate and disease control rate, irrespective of baseline PD-L1 status, with the addition of a gamma list to the centric and abraxing standard of care doublet, which received accelerated approval for the treatment of PD-L1 high but not PD-L1 low frontline TNBC patients. Third, data from ARCA's collaboration, a phase 1b study evaluating aganalysib and a novel checkpoint inhibitor-free regimen that includes a trumadenant, their dual adenosine receptor antagonist, endoxyl, in patients with relapsed refractory triple negative breast cancer and ovarian cancer were also presented at San Antonio Breast in December and showed an increase in response rate with the addition of aganalysib to the novel doublet therapy in both indications. And most recently, in the first quarter of 2021, we presented data at AXO-GU from MERIA-275, our randomized double-blind placebo-controlled Phase II study in collaboration with BMS, evaluating aganalysib in combination with Afevo in patients with advanced urothelial cancer. These data show improvements in response rates, disease control rates, and progression-free survival, particularly in patients with low levels of PD-L1 expression, who are known to not respond well to checkpoint inhibitor alone, and suggest the addition of aganalysib to standard-of-care Opdivo monotherapy can improve patient outcomes. Our strong execution and steady progress have propelled aganalysib forward with signals of activity across diverse settings, including double and triple combinations in the first, second, and third line, and also across multiple solid tumors, which Brian will review in more detail. These data lead us increasingly confident in the potential of aganalysib to improve responses in patients with some of the greatest unmet needs in oncology. Moving to our high-level thoughts regarding future development opportunities for aganalysib, in frontline TNBC, our path forward in combination with concentric and abraxane will be a function of our maturing data, which we will be presenting on July 27th, and again in the fourth quarter of 2021. We plan to cut the data as close to the end of the first half of 2021 as possible to have the most robust data set possible this summer. Additional data will be presented in the fourth quarter of this year, and completion of enrollment is on track for the second half of the year. Our current plan in bladder cancer is to focus on the PD-L1 low population who represent the majority of second-line bladder cancer patients and are also the patients with the greatest unmet need. Checkpoint inhibitors provide little to no benefit in these patients, with some approvals being limited to the PD-L1 high patient population, as with Keytruda and Tricentris in front-line urethral cancer. While our data suggests GAN elicit could be of benefit to all patients regardless of PD-L1 status, we plan to initially focus on PO and low patients, given the magnitude of the aganalysib benefit seen in these patients over Opdivo monotherapy, such that it should be possible to demonstrate the benefit of adding aganalysib to Opdivo in a relatively smaller number of patients, enabling a smaller registration trial, which can therefore be faster and less expensive to conduct. 2021 is poised to be a year of meaningful data updates and continued execution, and our strong balance sheet from the $92 million public offering in Q1 leaves us well-positioned to continue executing on the development of a GAN ELISIB to demonstrate the potential of our first-in-class and wholly-owned max-rate targeting therapeutic. With that, I'll turn the call over to Brian.

Disclaimer

This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

-

-